<DOC>
	<DOCNO>NCT01691495</DOCNO>
	<brief_summary>Fondaparinux anticoagulant use prevention treatment thromboembolic disease . It recently approve European Union ( EU ) treatment patient isolated superficial vein thrombosis ( SVT ) , i.e . without concomitant deep vein thrombosis ( DVT ) , low limb . As part EU approval , GlaxoSmithKline ( GSK ) commit evaluate physician ' adherence fondaparinux prescribe information regard proper diagnosis dose treatment SVT . The primary objective evaluate physician ' adherence fondaparinux prescribe information treatment patient SVT without concomitant DVT . The study design non-interventional , retrospective chart review patient prescribed fondaparinux treat SVT . The study conduct several EU country . ARIXTRA® register trademark GlaxoSmithKline group company .</brief_summary>
	<brief_title>ARIXTRA® Adherence SVT Patients .</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>Diagnosis SVT Prescribed fondaparinux treatment SVT Age 18 year old Patients involve clinical trial could influence SVT treatment observational period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Physician Adherence</keyword>
	<keyword>superficial vein thrombosis</keyword>
	<keyword>Fondaparinux</keyword>
</DOC>